Potential Use of a Novel Anti-Herpesviral Drug, Pritelivir, for the Treatment of Genital Herpes in Pregnancy
Date: December 19, 2024
Time: 12:00 - 1:00 pm
Presented by
Valentina Fokina Bryant, PhD
UTMB, OB&GYN Maternal-fetal Pharmacology and Bio-development laboratories
On December 19th, numerous faculty, clinicians and researchers attended a presentation by Valentina Bryant, PhD highlighting Dr. Bryant's research on the placental disposition of novel anti-herpesviral drugs and the ongoing development of medications for the treatment of the pregnant patients. Dr. Bryant’s presentation discussed her current research aiming to provide data on placental disposition of pritelivir as well as its reproductive toxicity as crucial steps in preclinical development of this novel drug for its use during pregnancy.
Dr. Bryant holds a Bachelor of Science in Biology from the Novosibirsk State University, Russia, and obtained her Ph.D. in Pharmacology and Toxicology from UTMB. Her doctoral research was focused on studying the pharmacokinetics of bupropion and its pharmacologically active metabolites in pregnancy. During her postdoctoral training at UTMB Dr. Bryant investigated the role of membrane uptake and efflux transporters on the placental passage of pravastatin. Dr. Bryant has also taken part in multiple projects studying the biotransformation of several medications by hepatic and placental metabolic enzymes as well as projects assessing in vitro and ex vivo transplacental permeability of selected nanomaterials.
